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Abstract
Background: Arterial hyperenhancement and washout on computed tomography and magnetic resonance
imaging (MRI) are described by all major guidelines as specific criteria for non-invasive diagnosis of hepatocellular
carcinoma (HCC). However, publications on the quantitative assessment of washout in MRI are lacking. Therefore,
we evaluated a method for quantitatively measuring and defining washout in MRI in order to determine a cutoff
value that allows objective HCC diagnosis.
Methods: We analyzed all patients who underwent liver transplantation for cirrhosis or liver resection for HCC at
our institution between 2003 and 2014. Washout was quantitatively investigated by placing a 25-mm2 region of
interest (ROI) over each nodule and two 25-mm2 ROIs over adjacent liver parenchyma. The percentage signal ratio
(PSR = 100 × ratio of signal intensity of adjacent liver to that of the lesion) was calculated for each series in both
groups. Accordingly, this quantitative measurement was compared to a qualitative approach.
Results: A total of 16 hypervascularized non-HCC nodules and 69 HCC nodules were identified. Interobserver
reliability was reasonably good for the measurement of PSRs and readers showed a substantial agreement for the
qualitative assessment. In the HCC group, the median PSR was 116.2 at equilibrium and 112.9 in the delayed phase.
In the non-HCC group, the median PSR was 93.8 at equilibrium and 96.0 in the delayed phase. Receiver operating
characteristic analysis indicated areas under the curve of 0.902 (p < 0.001) and 0.873 (p < 0.001) at equilibrium and in
the delayed phase. PSR values of 102 at equilibrium and 101.5 in the delayed phase led to the highest Youden’s
index of 0.82 and 0.77, respectively. These PSR cutoffs yielded sensitivities of 82 and 77 %, respectively, with
specificities of 100 %. The sensitivity for the qualitative assessment of washout was 88 and 93 % and the specificity
was 48 and 56 %. For the classification of HCC, sensitivity yielded 95 and 97 % and specificity was 68 and 56 %,
respectively.
Conclusion: Quantitatively measuring HCC washout in MRI is easy and reproducible. It can objectify and support
diagnosis of HCC. However, the quantitative measurement of washout can only serve as one of several
components of HCC assessment.
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Background
Hepatocellular carcinoma (HCC) is one of the most
common cancers, with around 750,000 new cases diag-
nosed annually worldwide [1, 2]. The incidence con-
tinues to increase, mainly due to the still increasing
numbers of hepatitis B virus and hepatitis C virus infec-
tions [3–5]. As most patients with HCC suffer from liver
cirrhosis and HCC exhibits specific enhancement on im-
aging due to the liver’s dual blood supply, the diagnosis
of HCC has been simplified considerably. Arterial hyper-
enhancement and washout of contrast media on portal
venous or delayed phase imaging of nodules >1 cm in
size enable a final diagnosis of HCC without biopsy in
cirrhotic patients based on all major guidelines, such as
those from the American Association for the Study of
Liver Diseases, the European Association for the Study of
the Liver, and the National Comprehensive Cancer Net-
work [1, 6, 7]. The Liver Imaging Reporting and Data Sys-
tem, a classification system for hepatic nodules, also relies
primarily on the washout of suspicious nodules [8].
Nonetheless, the evidence for current practice is weak.
Washout is highly specific for HCC detection [9–11],
but the decision of whether a certain nodule exhibits
washout or not is based solely on the subjective impres-
sion of the radiologist. Only Liu et al. [12] quantitatively
assessed washout and provided a cutoff value for multi-
phase computed tomography (CT). Although most au-
thors consider magnetic resonance imaging (MRI)
superior to CT for HCC imaging [9, 13–15], published
studies quantitatively assessing washout in MRI are lack-
ing. Therefore, the purpose of the current investigation
was to quantitatively define washout in contrast-
enhanced dynamic MRI in order to provide a cutoff
value that allows objective HCC diagnosis.
Methods
Patients and study design
This study was approved by the responsible ethical body.
The need for written consent was waived due to the
retrospective analysis of clinical data. Patient records
and information were anonymized and de-identified
prior to analysis.
We recruited two patient groups: patients with hyper-
vascularized non-HCC nodules and patients with
histology-confirmed HCC. Therefore, we selectively
searched our database for all patients treated between
2003 and 2014; patients treated before 2003 lacked suit-
able MRI and mainly underwent MR-angiography with-
out dynamic phase imaging or imaging without fat
saturation.
The non-HCC nodule group was recruited from all
patients who underwent liver transplantation at our in-
stitution. Additional inclusion criteria were proof of cir-
rhosis in the final pathology report, no proof of HCC in
the final pathology report, hypervascular lesion visible
on pre-operative MRI, dynamic phase imaging with add-
itional delayed phase imaging (Table 1), and sufficient
image quality. The HCC nodule group was not recruited
from liver transplant patients. Instead, in order to ensure
that the lesion mentioned in the pathology report was
identical to the one measured in the MRI, we assembled
this group from a population of patients who underwent
resection at our institution. To correlate the respective
lesions without any doubt, we further restricted our re-
cruitment to patients with postoperative cross-sectional
imaging, which allowed us to confirm that the measured
lesion was within the resected liver specimen. Additional
inclusion criteria were proof of cirrhosis in the final
pathology report, proof of HCC in the final pathology
report, lesion visible on pre-operative MRI, dynamic
phase imaging with additional delayed phase imaging
(Table 1), sufficient image quality and nodules in the
pathology report that were unequivocally correlated to
nodules visualized on pre-operative MRI and postopera-
tive cross-sectional imaging.
MRI and contrast medium
MRI was performed with different scanners: 1.5 T Son-
ata®, 1.5 T Avanto®, 3 T Trio®, or 3 T Skyra® (all Siemens
Healthcare, Germany). All patients underwent a similar
Table 1 Detailed imaging parameters of the magnetic resonance imaging instruments used in the current investigation
Sonata® Avanto® Trio® Skyra®
T2wa tra T2wa tra T2wa tra T2wa tra
T1w in/opposed phase b tra T1w in/opposed phase b tra T1w in/opposed phase b tra T1w in/opposed phase b tra
Diffusion-weighted imaging tra Diffusion-weighted imaging tra Diffusion-weighted imaging tra Diffusion-weighted imaging tra
4x T1w fs (native, arterial, portal
venous, equilibrium) c
4x T1w fs (native, arterial, portal
venous, equilibrium) d
4x T1w fs (native, arterial, portal
venous, equilibrium) d
4x T1w fs (native, arterial, portal
venous, equilibrium) d
T1w b tra/cor (delayed) T1w b tra (delayed) T1w b tra (delayed) T1w b tra (delayed)
tra transversal, cor coronal
a T2-weighted half-Fourier acquisition single-shot turbo spin-echo sequence (HASTE)
b T1-weighted fat-suppressed fast low-angle shot gradient echo sequence (FLASH®)
c T1-weighted fat-suppressed multi-phase contrast-enhanced series (FL 3d)
d T1-weighted fat-suppressed multi-phase contrast-enhanced series (VIBE®)
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imaging protocol comprised of four dynamic, contrast-
enhanced, T1-weighted fat saturated, three-dimensional
acquisitions and a delayed T1-weighted fat saturated
transversal acquisition. More detailed imaging parame-
ters are given in Table 1.
The arterial, portal venous, equilibrium and delayed
phases started 20, 45, 90 and 150–180 s, respectively, after
the administration of contrast material using a power in-
jector (Accutron MR®; Medtron, Germany). The contrast
agents were Magnevist® (gadolinium-diethylenetriamine-
pentacetate; Bayer Schering Pharma AG, Germany) or
Dotarem® (gadolinium-1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid; Guerbet, France). Patients investi-
gated with liver-specific contrast agents, such as Primo-
vist® (gadoxetate disodium; Bayer Schering Pharma AG,
Germany) were excluded due to entirely different contrast
characteristics on delayed-phase imaging.
Quantitative image analysis
Hypervascular nodules were identified visually in con-
sensus by two board-certified radiologists with several
years of experience in cross-sectional HCC imaging.
Nodules already presenting as hyperintense in the native
phase were excluded. The diameter of each nodule was
recorded and a 25-mm2 circular region of interest (ROI)
drawn manually over the nodule. The mean signal inten-
sity (SI) was documented by both radiologists in separate
evaluation sessions. A maximum of three nodules could
be evaluated in a single patient. If a nodule had hyper-
vascular and non-hypervascular parts, e.g., due to necro-
sis, then the ROI was placed over the hypervascular
part. Subsequently, two identical ROIs were placed over
the adjacent liver parenchyma outside the nodule (Fig. 1)
and the SIs of these ROIs averaged.
Liu et al. [12] calculated the percentage attenuation ratio,
attenuation change and relative washout ratio, concluding
that the percentage attenuation ratio was the most useful
parameter for differentiating between HCC and non-HCC.
In our case, calculating a value analogous to the percentage
attenuation ratio seemed reasonable because the SI in MRI
is not an absolute measurement, but an arbitrary value. As
MRI measures the SI instead of X-ray attenuation, we
named this proportional measure the percentage signal ratio
(PSR). The PSR was calculated for all contrast-enhanced
phases using the following formula:
PSR ¼ 100 AS=LSð Þ
where AS (adjacent SI) corresponds to the average of
two areas adjacent to the lesion and LS is the SI of the
lesion. ROIs were placed at corresponding coordinates
in all phases.
Qualitative image analysis
The visually identified nodules were evaluated independ-
ently in a separate session by two blinded readers experi-
enced in cross-sectional HCC imaging. The readers were
asked to classify nodules as having washout or not and if
suspicious or not suspicious for HCC. The results of this
qualitative evaluation were compared to the quantitative
approach described above.
Pathology
All explanted livers were sectioned into parallel 5-10-
mm slices. Afterwards, specimens from suspicious areas
were stained for further investigation by microscopy. In
unclear cases, additional staining and procedures were
performed at the pathologist’s discretion to obtain a final
diagnosis.
Computational and statistical analysis
For ROI placement and SI measurement, we used Aqua-
rius.NET Viewer® version 4.4.8.85 (Terarecon, USA). Pri-
mary data collection and PSR calculations were carried
Fig 1 Measurement of signal intensities in a nodule containing hypervascular and non-hypervascular parts due to necrosis. T1- weighted fat-suppressed
images in the (a) arterial phase and (b) equilibrium phase. The lesion ROI (yellow) was placed over the hypervascular part. Two identical ROIs were placed
over the adjacent liver parenchyma outside the nodule (red) in order to average the signal intensity
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out in Excel® 2013 (Microsoft Corporation, USA). Statis-
tical analyses were performed in SPSS® version 22 (IBM
Corporation, USA). Interobserver variability for categor-
ical variables was measured by calculating kappa values
and using the intraclass correlation coefficient for inter-
val variables. Groups were compared using the Mann-
Whitney U test as the distribution of PSR exhibited
skewness in some settings. The significance level was
chosen as α = 0.05. Receiver operating characteristic
(ROC) analysis was performed using the dedicated
ROC-curve tool in SPSS. To determine the optimal cut-
off value we calculated Youden’s index for each given
PSR value in each imaging phase [16].
Results
Initially, the liver transplantation group included 200 pa-
tients and the resection group 287 patients. A total of
184 and 223 patients were excluded from the respective
groups for various reasons. Thus, the final number of
patients in the liver transplantation and resection groups
were 16 and 64, respectively (Fig. 2). In the liver trans-
plantation group, 16 hypervascular non-HCC nodules
were analyzed (mean size 15 ± 3.5 mm, range 10–
22 mm). In the resection group five patients had two
nodules, and a total of 69 HCC nodules were analyzed
(mean size 62 ± 45.8 mm, range 11–174 mm). Most tu-
mors were moderately differentiated (G1, n = 12; G2, n
= 49; G3, n = 8). The quantitative analysis showed rea-
sonably good interobserver reliability for the computed
PSRs in the respective dynamic phases. Intraclass correl-
ation coefficients yielded 0.68, 0.69. 0.72, 0.69 and 0.61
for the native, arterial, portal venous, equilibrium and
late dynamic imaging phase, respectively [17].
All visually depicted lesions in the non-HCC group
were truly hypervascular according to the PSR. The
later the phase, the greater the convergence of the
SI of the nodule and the SI of the adjacent liver,
yielding median PSRs that approached 100 (76.4,
90.9, 93.8 and 96.0 in the arterial, portal venous,
equilibrium and delayed phases, respectively; Table 2
and Fig. 3). Even in the delayed phase, the median
PSR was considerably less than 100. Yet, 2 of the 16
non-HCC nodules (12.5 %) had PSRs >100 in the
equilibrium phase (101.5, 100.3), meaning that these
nodules had slightly lower SIs than the adjacent liver
in terms of washout.
In the second group, all HCC nodules exhibited sub-
stantial hypervascularization (Table 2). A majority of
these nodules had SIs in later imaging phases that were
markedly lower than the SIs of adjacent liver paren-
chyma in terms of washout, yielding median PSRs >100
(73.6, 106.8, 116.2 and 112.9 in the arterial, portal ven-
ous, equilibrium and delayed phases, respectively; Table 2
and Fig. 3). No washout was observed for 11 of the 69
Fig 2 Flowchart of patient inclusion in the two study groups. *Four patients were excluded from the resection/HCC group due to non-measurable
lesions because of diffuse tumor (n = 2 patients) and the presence of additional adenoma in the resected specimen (n = 2 patients). Therefore, an
unequivocal lesion-to-lesion correlation between MRI and the pathology report was not possible
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HCC nodules (15.9 %) in the equilibrium phase and 14
of the 69 HCC nodules (20.2 %) in the delayed phase.
Significantly different PSRs between the HCC and
non-HCC groups were found in all but the arterial con-
trast phase (PSRnative 128.3 vs. 94.6, p < 0.001; PSRarterial
73.6 vs. 76.4, p = 0.344; PSRvenous 106.8 vs. 90.9, p =
0.004; PSRequilibrium 116.2 vs. 93.8, p < 0.001; PSRdelayed
112.9 vs. 96.0, p < 0.001).
The ROC analysis clearly indicated that data from the
arterial phase were near the “line of no discrimination”,
with an area under the curve of only 0.424. The portal
venous, equilibrium and delayed phases more effectively
discriminated HCC nodules from non-HCC nodules,
with areas under the curve of 0.732, 0.902 and 0.873, re-
spectively (Fig. 4). Cutoff values of 102.0 at equilibrium
and 101.5 in the delayed phase led to the highest
Youden’s index of 0.82 and 0.77, respectively. PSR cut-
offs of 102.0 at equilibrium and 101.5 in the delayed
phase yielded sensitivities of 82 and 77 %, respectively,
with specificities 100 % (Fig. 3).
In the qualitative analysis, both readers showed a sub-
stantial level of agreement for the subjective assessment
of washout (Kappa 0.698, p < 0.001) and the classifica-
tion of HCC (Kappa 0.672, p < 0.001) [18]. Reader 1 cor-
rectly classified 64 of 84 nodules as either having
washout or no washout, the second reader correctly
classified 59 of 84 nodules. This yields a sensitivity of 88
and 93 % and a specificity of 48 and 56 % for washout.
In the second step reader 1 classified 76 of 84 nodules
correctly as either HCC or non-HCC, and the second
reader had a rate of 75 of 84, resulting in a sensitivity
and specificity of 95/68 % and 97/56 %, respectively.
Table 2 Signal intensities (SIs) over the nodule and adjacent liver parenchyma and the resulting percentage signal ratio (PSR) for
each contrast-enhanced phase. Data are presented as median (Q1/Q3)
Arterial Portal venous Equilibrium Delayed
Nodule
(SI)
Liver (SI) PSR Nodule
(SI)
Liver (SI) PSR Nodule
(SI)











































































p <0.001 0.233 0.005 <0.001
Fig 3 PSRs in HCC and non-HCC nodules in the different contrast phases. The median PSR for non-HCC (green) remained <100 in all contrast
phases, whereas most lesions in the HCC-group (red) exhibited considerable washout, corresponding to a PSR >100. The overlap was smallest in
the equilibrium and delayed phases. The horizontal lines indicate cutoff values of 102 and 101.5, which provide the best discrimination between
HCC and non-HCC
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This corresponds to a Youden’s index of 0.63 and 0.53
for the classification of HCC. Of the two non-HCC nod-
ules exhibiting quantitative washout in equilibrium
phase, both were classified as HCC by both readers.
Discussion
An accurate description of tumor size and nodule number
is important for patient management. According to the
Milan and United Network of Organ Sharing criteria, only
patients with limited tumor load are amenable to liver
transplantation. Therefore, surgeons often demand exact
discrimination between HCC and non-HCC lesions, espe-
cially in patients with severe liver cirrhosis and multiple
nodules with different contrast dynamics.
Liu et al. [12] were the first investigators to define a
quantitative cutoff for washout in CT. Their suggested
cutoff of 107 was chosen to maximize lesion detection
and yielded a sensitivity of 100 % and specificity of
75.8 % [12]. In our analysis we sought to maximize the
diagnostic performance of the quantitative method and
compared it to the qualitative evaluation by two experi-
enced readers. We found that the PSR was significantly
different between the HCC and non-HCC group. There-
fore, the PSR cutoff values of 102 at equilibrium and
101.5 in the delayed phase could serve as an aid for radi-
ologists to differentiate between HCC and non-HCC,
providing even more concise statements for liver
surgeons and other clinicians. Due to the resulting speci-
ficity and positive predictive values of 100 %, these cut-
offs would also be in line with the clinical guidelines for
non-invasive diagnosis of HCC [1, 6, 7]. In the future,
they could probably be used as one of several compo-
nents for automatic classification.
This study has several limitations. First, there may be
some bias due to small sample size and patient selection, as
the non-HCC group was transplanted due to cirrhosis and
only had hypervascular lesions that were not prospectively
felt to represent HCC. In contrast, the HCC group under-
went resection for lesions thought to be HCC. Second,
washout is only one of several criteria in the decision of
whether a lesion is suspicious for HCC. All lesions in the
HCC group that did not exhibit washout were correctly
classified as HCC due to other malignancy criteria such as
size, pseudocapsula or irregular pattern. However, this is in
concordance with the literature, in which around 20 % of
HCCs exhibit no washout [19–21]. Third, all explanted
livers were investigated by the pathologists according to a
standardized procedure and no HCC was found, but in the
final gross pathology report not all non-HCC lesions were
described in detail, including the two with washout, which
were also classified as HCC by both readers in this setting.
This leaves some uncertainty as to whether these lesions
were dysplastic nodules, vascular malformations or any
other type of hepatic lesion. Our primary purpose was to
Fig 4 Receiver operating characteristic analysis. The arterial phase provided no discrimination between HCC and non-HCC, with an area under
the curve of 0.424 (p = 0.344). Portal venous, equilibrium and delayed phases differentiated more effectively, with areas under the curve of 0.732
(p = 0.004), 0.902 (p < 0.001), and 0.873 (p < 0.001), respectively
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evaluate the methodology for quantification of washout in
MRI and all measurements were performed on MRI ma-
chines from a single manufacturer using roughly the same
imaging protocol. However, the use of different MRI scan-
ners from other manufacturers is unlikely to lead to differ-
ent results, as PSR is a relative and non-dimensional
measure. Furthermore, the exact location of the ROI may
have a considerable effect on the measured SI. Nonetheless,
by following the instructions for measurement described in
the Methods section, the intraclass correlation coefficients
in our analysis varied between 0.61 and 0.72 for the respect-
ive imaging phases, indicating a reasonably good interob-
server reliability. Our late-phase delay varied between 150
and 180 s, which is in concordance with Liu et al. [12] and
within the timing suggested by the new policy from the
Organ Procurement and Transplantation Network/United
Network for Organ Sharing [12, 22].
Conclusions
This study showed that quantitatively defining washout in
MRI of the liver by measuring the PSR is easy and repro-
ducible. We obtained results similar to those of Liu et al.
[12] using MRI instead of CT. The PSR cutoff values were
102 and 101.5 at equilibrium and in the delayed phase.
This approach can improve and objectify HCC diagnosis.
However, the quantitative measurement of washout can
only serve as one of several components of HCC assess-
ment. Additional research might be useful to further
optimize and validate our approach and set definitive cut-
off values derived from a larger sample.
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